Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies